TRIO-TECH INTERNATIONAL (TRT) Fundamental Analysis & Valuation

NYSEARCA:TRT • US8967122057

Current stock price

16.52 USD
+2.74 (+19.88%)
At close:
16.546 USD
+0.03 (+0.16%)
After Hours:

This TRT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TRT Profitability Analysis

1.1 Basic Checks

  • TRT had negative earnings in the past year.
  • In the past year TRT had a positive cash flow from operations.
  • In multiple years TRT reported negative net income over the last 5 years.
  • TRT had a positive operating cash flow in each of the past 5 years.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M 4M 6M 8M

1.2 Ratios

  • TRT's Return On Assets of -0.24% is in line compared to the rest of the industry. TRT outperforms 48.70% of its industry peers.
  • The Return On Equity of TRT (-0.33%) is comparable to the rest of the industry.
  • The Return On Invested Capital of TRT (0.49%) is comparable to the rest of the industry.
  • TRT had an Average Return On Invested Capital over the past 3 years of 2.81%. This is significantly below the industry average of 10.92%.
Industry RankSector Rank
ROA -0.24%
ROE -0.33%
ROIC 0.49%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • TRT has a Operating Margin (0.43%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of TRT has declined.
  • TRT has a Gross Margin of 19.68%. This is in the lower half of the industry: TRT underperforms 77.39% of its industry peers.
  • In the last couple of years the Gross Margin of TRT has grown nicely.
Industry RankSector Rank
OM 0.43%
PM (TTM) N/A
GM 19.68%
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

5

2. TRT Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TRT is destroying value.
  • The number of shares outstanding for TRT has been increased compared to 1 year ago.
  • The number of shares outstanding for TRT has been increased compared to 5 years ago.
  • The debt/assets ratio for TRT has been reduced compared to a year ago.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • TRT has an Altman-Z score of 7.96. This indicates that TRT is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.96, TRT is in line with its industry, outperforming 60.00% of the companies in the same industry.
  • TRT has a debt to FCF ratio of 7.26. This is a slightly negative value and a sign of low solvency as TRT would need 7.26 years to pay back of all of its debts.
  • TRT has a Debt to FCF ratio (7.26) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that TRT is not too dependend on debt financing.
  • The Debt to Equity ratio of TRT (0.02) is better than 66.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 7.26
Altman-Z 7.96
ROIC/WACC0.04
WACC12.09%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 2.96 indicates that TRT has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.96, TRT perfoms like the industry average, outperforming 52.17% of the companies in the same industry.
  • TRT has a Quick Ratio of 2.72. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
  • TRT's Quick ratio of 2.72 is in line compared to the rest of the industry. TRT outperforms 59.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.72
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2

3. TRT Growth Analysis

3.1 Past

  • The earnings per share for TRT have decreased strongly by -130.03% in the last year.
  • Looking at the last year, TRT shows a very strong growth in Revenue. The Revenue has grown by 27.63%.
  • Measured over the past years, TRT shows a small growth in Revenue. The Revenue has been growing by 1.14% on average per year.
EPS 1Y (TTM)-130.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85%
Revenue 1Y (TTM)27.63%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%81.56%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

1

4. TRT Valuation Analysis

4.1 Price/Earnings Ratio

  • TRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 72.17% of the companies in the same industry are more expensive than TRT, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TRT is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 1055.11
EV/EBITDA 40.19
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. TRT Dividend Analysis

5.1 Amount

  • TRT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

TRT Fundamentals: All Metrics, Ratios and Statistics

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (4/24/2026, 8:11:45 PM)

After market: 16.546 +0.03 (+0.16%)

16.52

+2.74 (+19.88%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)02-13
Earnings (Next)05-11
Inst Owners22.53%
Inst Owner Change5.35%
Ins Owners27.02%
Ins Owner Change3.35%
Market Cap144.55M
Revenue(TTM)49.22M
Net Income(TTM)-109.00K
Analysts0
Price TargetN/A
Short Float %0.22%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.94
P/FCF 1055.11
P/OCF 122.09
P/B 4.31
P/tB 4.31
EV/EBITDA 40.19
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.02
FCFY0.09%
OCF(TTM)0.14
OCFY0.82%
SpS5.62
BVpS3.83
TBVpS3.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.24%
ROE -0.33%
ROCE 0.62%
ROIC 0.49%
ROICexc 0.93%
ROICexgc 0.93%
OM 0.43%
PM (TTM) N/A
GM 19.68%
FCFM 0.28%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
ROICexc(3y)5.18%
ROICexc(5y)N/A
ROICexgc(3y)5.18%
ROICexgc(5y)N/A
ROCE(3y)3.55%
ROCE(5y)N/A
ROICexgc growth 3Y-59.08%
ROICexgc growth 5YN/A
ROICexc growth 3Y-59.08%
ROICexc growth 5YN/A
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 7.26
Debt/EBITDA 0.28
Cap/Depr 45.68%
Cap/Sales 2.13%
Interest Coverage 3.37
Cash Conversion 47.28%
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.72
Altman-Z 7.96
F-Score4
WACC12.09%
ROIC/WACC0.04
Cap/Depr(3y)45.5%
Cap/Depr(5y)44.1%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.63%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%81.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.27%
EBIT growth 3Y-59.86%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-97.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.88%
OCF growth 3Y-44.07%
OCF growth 5Y-34.21%

TRIO-TECH INTERNATIONAL / TRT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRIO-TECH INTERNATIONAL?

ChartMill assigns a fundamental rating of 3 / 10 to TRT.


Can you provide the valuation status for TRIO-TECH INTERNATIONAL?

ChartMill assigns a valuation rating of 1 / 10 to TRIO-TECH INTERNATIONAL (TRT). This can be considered as Overvalued.


How profitable is TRIO-TECH INTERNATIONAL (TRT) stock?

TRIO-TECH INTERNATIONAL (TRT) has a profitability rating of 3 / 10.